Dr Gomella
Agarwal N et al. Orteronel for metastatic hormone-sensitive prostate cancer: A multicenter, randomized, open-label phase III trial (SWOG-1216). J Clin Oncol 2022;40(28):3301-9. Abstract
Armstrong AJ et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol 2022;40(15):1616-22. Abstract
Chi KN et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: Final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol. 2021;39(20):2294-303. Abstract
Clarke NW et al. Corrigendum to addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: Long-term survival results from the STAMPEDE trial. Ann Oncol 2020;31(3):442. Abstract
Fizazi K et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): A multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet 2022;399(10336):1695-707. Abstract
Fizazi K et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): Final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 2019;20(5):686-700. Abstract
Freedland SJ et al. Reasons for oncologist and urologist treatment choice in metastatic castration-sensitive prostate cancer (mCSPC): A physician survey linked to patient chart reviews in the United States. ASCO 2022;Abstract 5065.
Freedland SJ et al. Treatment patterns and survival in metastatic castration-sensitive prostate cancer in the US Veterans Health Administration. Cancer Med 2021;10(23):8570-80. Abstract
Gravis G et al. Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: Further analyses of CHAARTED and GETUG-AFU15 studies. Eur Urol 2018;73(6):847-55. Abstract
James ND et al. Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). Int J Cancer 2022;151(3):422-34. Abstract
Kyriakopoulos CE et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: Long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 2018;36(11):1080-7. Abstract
Scher HI et al. Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol 2016;34(12):1402-18. Abstract
Smith MR et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 2022;386(12):1132-42. Abstract
Dr Yu
Cetintas VB, Batada NN. Is there a causal link between PTEN deficient tumors and immunosuppressive tumor microenvironment? J Transl Med 2020;18(1):45. Abstract
Crabb SJ et al. CAPItello-280: A phase III study of capivasertib and docetaxel versus placebo and docetaxel in metastatic castration-resistant prostate cancer. Genitourinary Cancers Symposium 2023;Abstract TPS287.
Crabb SJ et al. Overall survival update for patients with metastatic castration-resistant prostate cancer treated with capivasertib and docetaxel in the phase 2 ProCAID clinical trial. Eur Urol 2022;82(5):512-5. Abstract
de Bono J et al. IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC). ESMO 2020;Abstract LBA4.
Esteban-Villarrubia J et al. Mechanisms of immune evasion in PTEN loss prostate cancer. Immuno 2024;4(4):444-60. Abstract
Gonzalez Velez M et al. Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis 2022;25(3):479-83. Abstract
Gupta S et al. Real-world overall survival and treatment patterns by PTEN status in metastatic castration-resistant prostate cancer. JCO Precis Oncol 2024;8. Abstract
Lotan TL et al. PTEN loss detection in prostate cancer: Comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort. Oncotarget 2017;8(39):65566-76. Abstract
Nizialek E et al. Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer. Prostate 2021;81(9):572-9. Abstract
Shore ND et al. A phase I study of capivasertib in combination with abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Genitourinary Cancers Symposium 2021;Abstract 85.
Stopsack KH et al. Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer. Clin Cancer Res. 2020 Jul 1;26(13):3230-3238. Abstract
Turnham DJ et al. The PTEN conundrum: How to target PTEN-deficient prostate cancer. Cells 2020;9(11):2342. Abstract
Zhang J-Y et al. Prognostic value of PTEN in de novo diagnosed metastatic prostate cancer. Asian J Androl 2021;24(1):50-5. Abstract
Dr George
Sweeney C et al. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): A multicentre, randomised, double-blind, phase 3 trial. Lancet 2021;398(10295):131-42. Abstract
Turner N et al. Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Results from the Phase III CAPItello-291 trial. San Antonio Breast Cancer Symposium 2022;Abstract GS3-04.
Zhang J et al. A phase I study of the pharmacokinetics and safety of ipatasertib, an Akt inhibitor in Chinese patients with locally advanced or metastatic solid tumors. Clin Ther 2025;47(2):128-34. Abstract